The study is being planned to evaluate long term safety of Desidustat with CKD patient.~Total 1004 population i.e 502 dialysis dependent, 502 dialysis independent.
A Phase 4, 52 week, single arm, multicentre post marketing surveillance to evaluate the safety of Desidustat for the treatment of anemia in subjects with chronic kidney disease (CKD)